eXoZymes (EXOZ) Competitors $10.00 -0.18 (-1.77%) As of 07/8/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock EXOZ vs. AURA, ATXS, DBVT, AVIR, ANNX, AVTE, RCKT, GLUE, OLMA, and AARDShould you be buying eXoZymes stock or one of its competitors? The main competitors of eXoZymes include Aura Biosciences (AURA), Astria Therapeutics (ATXS), DBV Technologies (DBVT), Atea Pharmaceuticals (AVIR), Annexon (ANNX), Aerovate Therapeutics (AVTE), Rocket Pharmaceuticals (RCKT), Monte Rosa Therapeutics (GLUE), Olema Pharmaceuticals (OLMA), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. eXoZymes vs. Its Competitors Aura Biosciences Astria Therapeutics DBV Technologies Atea Pharmaceuticals Annexon Aerovate Therapeutics Rocket Pharmaceuticals Monte Rosa Therapeutics Olema Pharmaceuticals Aardvark Therapeutics eXoZymes (NASDAQ:EXOZ) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations. Do institutionals & insiders hold more shares of EXOZ or AURA? 96.8% of Aura Biosciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 5.4% of Aura Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is EXOZ or AURA more profitable? eXoZymes' return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets eXoZymesN/A N/A N/A Aura Biosciences N/A -58.63%-49.74% Do analysts recommend EXOZ or AURA? Aura Biosciences has a consensus price target of $22.00, suggesting a potential upside of 252.00%. Given Aura Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Aura Biosciences is more favorable than eXoZymes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media refer more to EXOZ or AURA? In the previous week, eXoZymes had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 4 mentions for eXoZymes and 0 mentions for Aura Biosciences. eXoZymes' average media sentiment score of 1.37 beat Aura Biosciences' score of 0.00 indicating that eXoZymes is being referred to more favorably in the media. Company Overall Sentiment eXoZymes Positive Aura Biosciences Neutral Which has higher earnings & valuation, EXOZ or AURA? eXoZymes has higher revenue and earnings than Aura Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeXoZymes$70K1,195.71-$5.86MN/AN/AAura BiosciencesN/AN/A-$86.92M-$1.90-3.29 SummaryeXoZymes beats Aura Biosciences on 7 of the 12 factors compared between the two stocks. Get eXoZymes News Delivered to You Automatically Sign up to receive the latest news and ratings for EXOZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXOZ vs. The Competition Export to ExcelMetriceXoZymesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.21M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E RatioN/A20.8026.9720.11Price / Sales1,195.71286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book8.007.487.985.56Net Income-$5.86M-$55.04M$3.16B$248.40M7 Day Performance-1.96%2.44%2.36%4.67%1 Month Performance-28.37%1.90%2.15%6.64%1 Year PerformanceN/A4.35%33.78%21.31% eXoZymes Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXOZeXoZymesN/A$10.00-1.8%N/AN/A$85.21M$70K0.0029Positive NewsAURAAura Biosciences1.8841 of 5 stars$6.59+2.0%$22.00+233.8%-14.6%$331.28MN/A-3.4750Positive NewsATXSAstria Therapeutics1.7941 of 5 stars$5.81+1.4%$30.00+416.4%-31.4%$327.86MN/A-3.1130DBVTDBV Technologies3.5978 of 5 stars$11.54+12.0%$14.75+27.8%+163.8%$316.05M$4.15M-2.3580Gap UpAVIRAtea Pharmaceuticals2.3316 of 5 stars$3.67+1.1%$6.00+63.5%+11.3%$314.08MN/A-2.2270ANNXAnnexon2.6579 of 5 stars$2.86+1.6%$12.50+337.8%-43.3%$313.23MN/A-2.4260News CoveragePositive NewsAVTEAerovate TherapeuticsN/A$10.80-0.4%N/A-82.8%$313.04MN/A-3.6120High Trading VolumeRCKTRocket Pharmaceuticals4.8804 of 5 stars$2.93+1.7%$18.60+534.8%-85.7%$312.90MN/A-1.11240Trending NewsGLUEMonte Rosa Therapeutics1.3291 of 5 stars$5.05+6.7%$15.33+203.9%+30.1%$310.38M$75.62M63.0890OLMAOlema Pharmaceuticals1.726 of 5 stars$4.43-2.5%$24.50+453.5%-58.0%$302.83MN/A-2.2070Positive NewsAARDAardvark TherapeuticsN/A$13.92+3.0%$33.00+137.1%N/A$302.06MN/A0.0018 Related Companies and Tools Related Companies Aura Biosciences Competitors Astria Therapeutics Competitors DBV Technologies Competitors Atea Pharmaceuticals Competitors Annexon Competitors Aerovate Therapeutics Competitors Rocket Pharmaceuticals Competitors Monte Rosa Therapeutics Competitors Olema Pharmaceuticals Competitors Aardvark Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXOZ) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eXoZymes Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eXoZymes With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
